Nilotinib monohydrochloride尼洛替

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nilotinib monohydrochloride monohydrate

CAS No. : 923288-90-8

MCE 国际站：Nilotinib monohydrochloride monohydrate

产品活性：Nilotinib monohydrochloride monohydrate 是一种二代酪氨酸酶抑制剂，有效抑制 BCR-ABL 及其突变体。

研究领域：Protein Tyrosine Kinase/RTK  |  Autophagy

作用靶点：Bcr-Abl  |  Autophagy

In Vitro: Nilotinib (AMN107) monohydrochloride monohydrate, selective Abl inhibitor, is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than imatinib while being significantly more potent compared with imatinib (IC₅₀<30 nM), also maintains activity against most of the BCR-ABL point mutants that confer Imatinib resistance.
?Nilotinib monohydrochloride monohydrate demonstrates significant antitumor efficacy against GIST xenograft lines and imatinib-resistant GIST cell lines which parent cell lines GK1C and GK3C shows imatinib sensitivity with IC₅₀ of 4.59±0.97 μM and 11.15±1.48 μM, respectively, imatinib-resistant cell lines GK1C-IR and GK3C-IR shows Imatinib resistance with IC₅₀ values of 11.74±0.17 μM (P<0.001) and 41.37±1.07 μM (P<0.001), respectively.

In Vivo: Nilotinib monohydrochloride monohydrate (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft.
?Nilotinib monohydrochloride monohydrate has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Cell Death Library  |  Dasatinib  |  Nocodazole  |  Imatinib  |  Ponatinib  |  Nilotinib  |  Bosutinib  |  Asciminib  |  Degrasyn  |  Rebastinib  |  Olverembatinib  |  AT9283  |  KW-2449  |  LXH254  |  Bafetinib  |  DPH  |  AST 487  |  Flumatinib  |  PD173955  |  Vodobatinib  |  BV02  |  GNF-2  |  XL228  |  GNF-7  |  Cenisertib  |  GNF-5  |  SIAIS178

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds